Myriad Genetics Licenses Gene for Hereditary Breast, Ovarian Cancers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Wednesday that it has obtained an exclusive license to the RAD51C gene, which has been associated with an increased risk for hereditary breast and ovarian cancers.

The license from a consortium of German researchers gives Myriad the exclusive global rights, with co-exclusive rights in Germany, to provide commercial testing for the gene.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.